Excludes commercial-in-confidence projects.
Research since 2008 is shown below.
Open access indicates that an output is open access.
Brown, MP, Ebert, LM & Gargett, T 2019, 'Clinical chimeric antigen receptor-T cell therapy: a new and promising treatment modality for glioblastoma', Clinical and Translational Immunology, vol. 8, no. 5, article no. e1050, pp. 1-20.
Open access 1 1
Gargett, T, Truong, N, Ebert, LM, Yu, W & Brown, MP 2019, 'Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype', Cytotherapy, online, pp. 1-10.
Mencel, J, Gargett, T, Karanth, N, Pokorny, A, Brown, MP & Charakidis, M 2019, 'Thymic hyperplasia following double immune checkpoint inhibitor therapy in two patients with stage IV melanoma', Asia Pacific Journal of Clinical Oncology, online, pp. 1-4.
Zhang, P, Raju, J, Ullah, MA, Au, R, Gargett, T, Brown, MP & Tey, SK 22 total authors 2019, 'Phase I trial of inducible caspase 9 T cells in adult stem cell transplant demonstrates massive clonotypic proliferative potential and long-term persistence of transgenic T cells', Clinical Cancer Research, vol. 25, no. 6, pp. 1749-1755.
1 1 22
Ebert, LM, Yu, W, Gargett, T & Brown, MP 2018, 'Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology', Biochemical Society Transactions, vol. 46, no. 2, pp. 391-401.
3 2 6
Gargett, T, Abbas, MN, Rolan, P, Price, JD, Gosling, KM, Ferrante, A, Ruszkiewicz, A, Atmosukarto, II, Altin, J, Parish, CR & Brown, MP 2018, 'Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma', Cancer Immunology Immunotherapy, vol. 67, no. 9, pp. 1461-1472.
5 3 4
Gargett, T, Yu, W, Dotti, G, Yvon, ES, Christo, SN, Hayball, JD, Lewis, ID, Brenner, MK & Brown, MP 2016, 'GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade', Molecular Therapy, vol. 24, no. 6, pp. 1135-1149.
Open access 72 70 5
Gargett, T & Brown, MP 2015, 'Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2', Cytotherapy, vol. 17, no. 4, pp. 487-495.
38 33 15
Gargett, T, Fraser, CK, Dotti, G, Yvon, ES & Brown, MP 2015, 'BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro', Journal of Immunotherapy, vol. 38, no. 1, pp. 12-23.
14 15 1
Gargett, T & Brown, M 2014, 'The inducible caspase-9 suicide gene system as a 'safety switch' to limit on-target, off-tumor toxicities of chimeric antigen receptor T-cells', Frontiers in Pharmacology, vol. 5, article no. 235, pp. 1-7.
Open access 99 85 21
Gargett, T, Bruber-Bauk, B, Garrod, T, Yu, W, Miller, DS, Major, L, Wesselingh, S, Suhrbier, A & Gowans, E 2014, 'Induction of antigen-positive cell death by the expression of Perforin, but not DTa, from a DNA vaccine enhances the immune response', Immunology and Cell Biology, vol. 92, no. 4, pp. 359-367.
15 16 27
Gargett, T, Grubor-Bauk, B, Miller, D, Garrod, T, Yu, S, Wesselingh, S, Suhrbier, A & Gowans, EJ 2014, 'Increase in DNA vaccine efficacy by virosome delivery and co-expression of a cytolytic protein', Clinical and Translational Immunology, vol. 3, article no. e18, pp. 1-7.
Open access 1
Garrod, T, Grubor-Bauk, B, Yu, S, Gargett, T & Gowans, EJ 2014, 'Encoded novel forms of HSP70 or a cytolytic protein increase DNA vaccine potency', Human Vaccines and Immunotherapeutics, vol. 10, no. 9, pp. 2679-2683.
4 5 1
Garrod, TJ, Bruber-Bauk, B, Gargett, T, Li, Y, Miller, DS, Wenbo, Y, Major, L, Burrell, CJ, Wesselingh, S, Suhrbier, A & Gowans, EJ 2014, 'DNA vaccines encoding membrane-bound or secreted forms of heat shock protein 70 exhibit improved potency', European Journal of Immunology, vol. 44, no. 7, pp. 1992-2002.
Open access 15 14 1
Garrod, TJ, Gargett, T, Yu, W, Major, L, Burrell, CJ, Wesselingh, S, Suhrbier, A, Grubor-Bauk, B & Gowans, EJ 2014, 'Loss of long term protection with the inclusion of HIV pol to a DNA vaccine encoding gag', Virus Research, vol. 192, pp. 25-33.
5 5 1
Brown, CY, Sadlon, T, Gargett, T, Melville, E, Zhang, R, Drabsch, Y, Ling, M, Strathdee, CA, Gonda, TJ & Barry, SC 2010, 'Robust, reversible gene knockdown using a single lentiviral short hairpin RNA vector', Human Gene Therapy, vol. 21, no. 8, pp. 1005-1017.
External engagement & recognition
|Amgen Inc||UNITED STATES|
|Australian National University||AUSTRALIA|
|Baylor College of Medicine||UNITED STATES|
|Houston Methodist Hospital||UNITED STATES|
|Institute of Medical and Veterinary Science||AUSTRALIA|
|Lipotek Pty Ltd||AUSTRALIA|
|QIMR Berghofer Medical Research Institute||AUSTRALIA|
|Queensland Institute of Medical Research||AUSTRALIA|
|Royal Adelaide Hospital||AUSTRALIA|
|Royal Darwin Hospital||AUSTRALIA|
|South Australian Health and Medical Research Institute (SAHMRI)||AUSTRALIA|
|University of Adelaide||AUSTRALIA|
|University of North Carolina at Chapel Hill||UNITED STATES|
|University of Queensland||AUSTRALIA|
|University of South Australia||AUSTRALIA|
|University of Texas||UNITED STATES|
|Women and Children's Health Research Institute||CANADA|